A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study

Table 1 Timing of procedures

	6 0/7- 13 6/7 weeks GA	Bi-weekly after enrollment	4 weeks after enrollment	16-20 weeks GA	26-30 weeks GA	28-30 weeks GA	34 weeks GA	36 weeks GA until delivery	6 weeks Post-Partum	As needed
Screening
Initial eligibility	●
Ultrasound	●
Consent	●
Randomization/Enrollment	●
Clinical Assessments
Physical exam	●
Medical history	●
Use of other medicines	●	●
Maternal Hb monitoring	●		●		●
BP Monitoring	●			●		●	●	●
Medication Activities
Instructions for medication use	●	●
Medication compliance^a		●
Resupply		●
Outcome Assessment
Preterm Birth									●
SGA									●
Preeclampsia/Eclampsia		●		●		●	●	●	●	●
Other maternal outcomes		●							●	●
Other fetal outcomes									●	●
Unanticipated medical care		●								●
Serious Adverse Events		●							●	●

^aMedication is supplied until 36 weeks GA; therefore duration of medication-related monitoring depends on GA at randomization

ISSN: 1471-2393